The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts. - Trial NCT04400760
Access comprehensive clinical trial information for NCT04400760 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by The University of The West Indies and is currently Recruiting. The study focuses on Platelet Dysfunction. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The University of The West Indies
Timeline & Enrollment
Phase 2/3
May 01, 2020
Jun 30, 2022
Primary Outcome
Platelet Reactions Units pre-DAPA Tx and post-DAPA Tx
Summary
Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the
 likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of
 which the mechanism has not been fully elucidated. The mechanistic effects of dapagliflozin
 on platelet function profiles have not yet been ascertained. It remains unclear if this
 reduction in cardiovascular death is mediated by decreased platelet reactivity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04400760
Non-Device Trial